C. R. Bard
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, C. R. Bard sits in the top decile of US sponsors by registered trial count (#290 of 15,742 sponsors by registered trial count).
C. R. Bard: 75 sponsored US clinical trials, 4 recruiting.
C. R. Bard sponsors 75 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 56 completed. 10 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arteriovenous Fistula, with 3 trials.
Top-decile sponsor footprint
C. R. Bard ranks in the top decile of sponsors by registered trial count (#290 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
56 of 69 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
75 total, page 1 of 2
Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)
NCT07016698
Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
NCT05945329
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
NCT04634916
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Venclose digiRF System Post Market Study
NCT05504070
Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae
NCT03506308
This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.
NCT06850259
This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the Home Setting.
NCT06666426
PureWick™ Adolescent Study
NCT06631313
PureWick™ France and U.S. At-Home Pilot Study
NCT05710718
Male External Catheters' Comparison of Comfort and Efficacy
NCT05955560
The Pristine Post-Market Study
NCT05228132
Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
NCT04261686
Caterpillar™ Arterial Embolization Device Post-Market Study
NCT04244370
STARS-R Registry: Retrospective Analysis of Poly-4-hydroxybutyrate (P4HB) Scaffold Use
NCT04195854
Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)
NCT02813577
SHERLOCK 3CG™ Diamond Tip Confirmation System
NCT03288766
Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon
NCT03193619
Impact of Fever Prevention in Brain Injured Patients
NCT02996266
Evaluating Safety and Effectiveness of Octenidine Dihydrochloride
NCT03140254
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)
NCT02790606
BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease
NCT02655887
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
NCT02649946
Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
NCT02649894
Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias
NCT02691962
A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair
NCT02712398
Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae
NCT02440022
Time and Motion Related to PICC Insertion Process and Catheter Tip Confirmation
NCT02498821
Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter
NCT02424383
Prospective Feasibility Trial of AccuCath 2.25" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department
NCT02449798
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
NCT02228564
Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
NCT02063672
Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs
NCT02792764
A Prospective, Multicenter All Comers Study of Phasix Mesh for Ventral or Incisional Hernia Repair
NCT02053168
Progel Vascular Sealant
NCT01959503
Study to Assess Electrocardiogram Waveforms Produced Through the Utilization of the Sherlock 3CG™ Tip Confirmation System
NCT03028090
A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.
NCT01961687
Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology
NCT01940354
Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
NCT01870401
Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic Surgery
NCT01867658
AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)
NCT01937195
AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use
NCT01943474
LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB)
NCT01628159
Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters
NCT01586026
GalaFlex Mesh in Facelift
NCT02053831
LEVANT 2 Safety Registry
NCT01790243
Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries
NCT01412541
NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study
NCT01394978
A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System
NCT01305564
Topical Antimicrobial Effectiveness Testing
NCT01366417
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 7 |
| Phase 4 | 3 |
Therapeutic Areas
Where C. R. Bard enrollment is open (later-stage tilt)
4 recruiting of 75 indexed (5% open); 56 completed (75%).
Phase mix: 10 late (III/IV) vs 4 early (I/II) (later-stage heavy).
Top condition: Arteriovenous Fistula (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
C. R. Bard: open-pipeline peers nationwide
Peers matched on 75 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
C. R. Bard sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 75 trials (± recruiting share)
- ECOG-ACRIN Cancer Research Group · 75 trials · 16% recruiting
- Hartford Hospital · 75 trials · 11% recruiting
- Inova Health Care Services · 75 trials · 29% recruiting
- Ionis Pharmaceuticals · 76 trials · 12% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Almirall, S.A. · 5% recruiting · 19 trials
- Cordis US · 5% recruiting · 19 trials
- Defense and Veterans Center for Integrative Pain Management · 5% recruiting · 19 trials
- DePuy Orthopaedics · 5% recruiting · 38 trials
Related
What to do with this C. R. Bard page
75 registered trials is a research-attention snapshot, not an endorsement of C. R. Bard or any single study.
- 4 of C. R. Bard's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Arteriovenous Fistula is the condition C. R. Bard studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arteriovenous Fistula trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
C. R. Bard pipeline card: 75 registered trials from official public datasets.Report a data error.